Resource Library

A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical

In this episode of Px Pulse, the Dapivirine Vaginal Ring is center stage. After decades of research and advocacy, the ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in…

Community/Advocacy

After The Ring Study: DREAM

DREAM, or Dapivirine Ring Extended Access and Monitoring, was a year long open-label extension (OLE) study launched by the International Partnership for Microbicides (IPM) in 2019 to assess how safe the ring is for the 940 HIV- women who participated in The Ring Study, and explores when, why, and how women use the ring.

Community/Advocacy

Safety, Adherence and HIV-1 Seroconversion in DREAM – An Open-label Dapivirine Vaginal Ring Trial

The Ring Study, a phase 3 trial in 1959 sexually active women (randomised 2:1), showed a favourable safety profile and a 31% HIV-1 infection risk reduction for a vaginal ring containing 25 mg of dapivirine, compared with a placebo ring. This article features a report on the DREAM study, which aimed to evaluate safety, adherence,…

Research

Final Results of Open-label Study of IPM’s Dapivirine Vaginal Ring Show Increased Use and Suggest Lower Infection Rates Compared to Earlier Phase III Study

This letter from the International Partnership for Microbicides outlines the results of an open-label study on the Dapivirine Vaginal Ring

Research

Results of open-label study of a vaginal ring for HIV prevention suggest women are interested in and willing to use it

This article from the Microbicide Trials Network shares the results of an open-label study of a vaginal ring for HIV prevention

Community/Advocacy, Demand Creation/Marketing, Research

Adherence to the Dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study

Adolescent girls and young women (AGYW) account for most new HIV infections in sub-Saharan Africa. WHO has endorsed oral PrEP and dapivirine vaginal ring (ring) for women at substantial risk of HIV infection. However, adherence to both products was lower among younger women in randomized placebo-controlled trials. The authors of this article assessed interim safety,…

Research

Microbicide Trials Network-042 – DELIVER Study

Microbicide Trials Network-042/DELIVER is a Phase IIIb open-label study designed to evaluate the safety and acceptability of the monthly dapivirine vaginal ring and oral PrEP in pregnant women.

Research

IAS 2021 Satellite Session: Bringing the Dual Prevention Pill to Market: Opportunities for HIV and Pregnancy Prevention and Implications for Future MPTs

This video-recorded session from IAS 2021 examines opportunities for bringing the Dual Prevention Pill to market as well as implications for future multipurpose prevention technologies.

CHARISMA Mobile: Developing a digital resource for empowerment counseling, community health clinic model for agency in relationships and safer microbicide adherence

CHARISMA is a PEPFAR- and USAID-funded empowerment counseling intervention designed to help women use oral pre-exposure prophylaxis and other antiretroviral-based HIV prevention technologies safely and effectively by addressing dynamics of their relationships with male partners, including exposure to intimate partner violence. The intervention, designed to be delivered by lay counselors, is being adapted into a…

Research, Service Delivery

MTN-045

Archived from the MTN website before it was taken down. Primary Objectives To determine heterosexual couples’ preferences for a DPP product to inform product delivery and future product design to maximize uptake and willingness to use among sub-Saharan African heterosexual couples. To assess the level of influence of the male partner on a woman’s preferences…

Research